現在の保管者数(10/9現在)
45,130
これまでの採取実績病院数
1,940施設
Cord Blood with Potential

Cord blood is drawing attention due to its potential in regenerative medicine and cellular therapies, such as diseases that cannot be fully treated at present, like central nervous system disorders (hypoxic-ischemic encephalopathy, cerebral palsy, hearing loss, traumatic encephalopathy and spinal cord injuries, etc.) as well as autoimmune disorders and autistic spectrum disorders and  autism. It is also being used for the treatment of refractory blood diseases, such as leukemia and aplastic anemia.

Foundation research is confirming how cord blood repairs disorders and damage as stem cells in the cord blood migrate (home in on) to the damaged area of the brain, where they relieve inflammation, adjust immunity and activate other cells (cytocrine secretion). Currently, clinical trials on human volunteers are ongoing.

Cerebral Palsy
Rate of incidence:2.2 out of 1,000 birth in Japan.
.
Autism
Rate of incidence:1 out of 100 birth in Japan.
.
Traumatic Brain Injury
This is a brain disorder due to a traffic accident or by falling.
.
Hearing Loss
Rate of incidence:1~2 out of 1,000 birth in Japan.
.
Hypoxic Ischemic Encephalopathy
This is a brain disorder due to disrupted blood flow to the brain at the time of still birth.
Some of  the children develops cerebral palsy.
.

Cord Blood Registry, the leading private bank in the USA, has released a brief review regarding the research and clinical use of the newborn cord blood for various brain disorders including cerebral palsy, traumatic brain injury, stroke, etc. The review says that many scientists believe the cord blood cells have a potential to facilitate repair of the damaged brain tissue. For detail, please read
Newborn Stem Cells from Cord Blood and the Brain.

State of Affairs in Clinical Studies using Autologous Cord Blood

  Japan:Reports up to June 2017

Condition Enrollment Institution Primary end date
Hypoxic-ischemic encephalopathy 6 Osaka City University Hospital February 2018
Infantile cerebral palsy 6 Kochi Medical School Hospital March 2023

  USA

Condition Enrollment Institution Primary end date
Autism 29 Sutter Health Completion (not yet announced)
Autistic spectrum disorder
(Phase I)
25 Duke University Completion (paper published)

Stem Cells Transl Med, 2017 Apr

Autistic spectrum disorder
(Phase II)
165 Duke University Recruiting subjects
(scheduled for completion in December 2018)
Cerebral palsy 63 Duke University Completion (announced at symposium)

2016, 14th International Cord Blood Symposium

Cerebral palsy 40 Georgia Regents University Recruiting subjects
(scheduled for completion in July 2018)
Cerebral palsy 20 Texas University Recruit of subjects  Completion
Hypoxic ischemic encephalopathy 52 Duke University Completion (paper published)

J Pediatr. 2014 May; 164(5):973-979

Hypoxic ischemic encephalopathy 160 Duke University Recruiting subjects
Hypoxic ischemic encephalopathy 20 New York Medical College Before start of subject recruitment
Hypoplastic left heart syndrome 10 Mayo Clinic Recruiting subjects (with case reports)

J Thorac Cardiovasc Surg. 2015 Mar; 149(3):e35-7

Type I diabetes 15 Florida University Completion (paper published)

Diabetes Care 2011 Dec; 34:2567-2569./
Exp Hematol. 2008 Jun; 36(6):710-715

All of the clinical trials listed above are using autologous cord blood. It is considered that the safety and efficiency are lowered when allogeneic cord blood is used.